Overview

Ghrelin Suppression by Octreotide in Prader-Willi

Status:
Unknown status

Trial end date:
2020-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to learn more about how octreotide (Sandostatin LAR® Depot) affects levels of ghrelin, hunger, and body weight in people with Prader-Willi Syndrome.

Phase:

N/A

Details

Lead Sponsor:

Oregon Health and Science University

Treatments:

Octreotide